CBG and Pain: Preclinical Evidence — J.P. Hemp Company



Health Topics — Pain & Inflammation

CBG and Pain: Preclinical Evidence

CBG outperformed THC in some nociception models and interacts with pain-relevant receptors through mechanisms distinct from CBD — what the preclinical research has found and why the human trial gap matters more in pain research than in most other domains.

Standard Research · Tier 2
Last Reviewed: August 2026
~1900 words
Preclinical — Animal Models and In Vitro Throughout
Archival research plate — preclinical study structure with animal model documentation in 19th-century engraving style
CBG pain preclinical research reference plate

CBG's pain research sits at an intersection of three mechanisms — TRPV1 receptor interaction, CB1 partial agonism, and the anti-inflammatory CB2 and PPAR-γ pathways documented in the inflammatory signaling article in this pillar. Understanding what each contributes to the preclinical pain picture requires treating them separately before considering how they might work together.

Preclinical — Animal Models and In Vitro Throughout

CBG's Pain-Relevant Receptor Profile

Pain research involves a more complex receptor landscape than most cannabinoid research domains. The primary cannabinoid pain mechanisms — CB1 agonism producing central and peripheral analgesia, TRPV1 activation and desensitization reducing nociceptor sensitivity, CB2 reducing the inflammatory environment that sensitizes pain fibers — are documented separately across the archive. CBG has documented activity at all three pathways, with a profile that is distinct from both THC and CBD in ways that matter for interpreting the preclinical pain findings.

CBG's Three Pain-Relevant Mechanisms
Mechanism
How It Works in Pain Contexts
CB1 Partial Agonism
CB1 receptors in the spinal cord dorsal horn and in peripheral sensory neurons modulate pain signal transmission — CB1 activation reduces the ascending pain signal. CBG's partial agonism at CB1 produces this effect at submaximal potency compared to THC. In nociception models, the partial agonism profile means CBG produces analgesic effects without the psychoactive consequences of full CB1 agonism, which is pharmacologically relevant even in preclinical contexts where psychoactivity cannot be directly measured.
TRPV1 Interaction
TRPV1 — the transient receptor potential vanilloid 1 channel — is expressed on nociceptive sensory neurons and is one of the primary transducers of heat, acid, and inflammatory pain signals. CBG interacts with TRPV1, with initial activation followed by desensitization at sustained exposure — the same pattern documented for CBD. Desensitized TRPV1 channels respond less vigorously to subsequent painful stimuli, reducing nociceptor sensitivity. This mechanism is particularly relevant to inflammatory pain where TRPV1 is sensitized by prostaglandins and other inflammatory mediators.
CB2 and Anti-inflammatory
Inflammatory pain is not simply a pain signal problem — it is a pain signal amplified by an inflammatory environment that sensitizes nociceptors, reduces their activation threshold, and recruits immune cells that release further sensitizing mediators. CBG's CB2 partial agonism and PPAR-γ activation reduce this inflammatory environment, which indirectly reduces pain sensitization. This pathway is covered in detail in the CBG and Inflammatory Signaling article in this pillar — it is mentioned here because it contributes to CBG's analgesic profile in inflammatory pain models specifically.

The Nociception Model Findings

Key Preclinical Findings — CBG in Pain Models

Nociception Comparison Studies: Multiple preclinical studies examining cannabinoids in standard nociception models — including the hot plate test, acetic acid writhing test, and formalin test — have documented that CBG produces analgesic effects at doses comparable to or exceeding those of THC in some models. The acetic acid writhing test, which measures visceral pain response, has shown CBG to be particularly active. The finding that CBG outperformed THC in some of these models is the most frequently cited pain finding in CBG's preclinical literature and warrants careful interpretation — see the field note below.

Inflammatory Pain Models: In carrageenan-induced paw edema models — a standard preclinical model of inflammatory pain — CBG has shown both anti-inflammatory and anti-hyperalgesic effects. Hyperalgesia is the phenomenon where inflamed tissue becomes abnormally sensitive to pain stimuli, a central feature of clinical inflammatory pain conditions. Reduction in carrageenan-induced hyperalgesia suggests CBG's anti-inflammatory mechanisms contribute to its analgesic profile beyond simple nociceptor modulation.

Colitis Pain Model: The Borrelli 2013 study documented in the Gut Health pillar — which examined CBG in a mouse model of IBD — also documented reduced colonic pain sensitivity alongside its anti-inflammatory findings. This is relevant here because visceral pain in inflammatory bowel disease involves both central sensitization and peripheral inflammation, making it a model where CBG's multi-mechanism profile is potentially more relevant than in simple nociception models.

Neuropathic Pain: Neuropathic pain — pain arising from nerve damage rather than tissue injury or inflammation — is one of the most difficult pain types to treat with existing medications and one of the primary targets of cannabinoid pain research. Specific CBG studies in neuropathic pain models are limited as of 2026. The TRPV1 and CB1 mechanisms are relevant to neuropathic pain biology, but direct neuropathic pain model evidence for CBG is not well-developed relative to CBD's more extensive neuropathic pain preclinical portfolio.

On the "More Potent Than THC" Finding — Careful Interpretation Required

The finding that CBG exceeded THC's analgesic effect in some nociception models has circulated widely in cannabinoid content and requires two important qualifications. First, these comparisons are at equivalent doses by weight — not at equivalent receptor activation levels. THC is a full CB1 agonist; CBG is a partial agonist with substantially lower CB1 potency. At very high doses, CBG's multi-mechanism profile (CB1 + TRPV1 + CB2 + PPAR-γ acting simultaneously) can produce larger total analgesic effects than THC's more selective CB1 mechanism in specific model contexts. This is not the same as saying CBG is a more potent analgesic than THC in any general sense.

Second, rodent nociception models — hot plate, writhing test, formalin — do not map cleanly onto human pain conditions. They measure reflex responses to acute painful stimuli, which is pharmacologically informative but clinically distinct from chronic inflammatory pain, neuropathic pain, or cancer pain. The comparison with THC in these models is a useful pharmacological data point. It is not a clinical claim.

How CBG Compares to CBD in Pain Research

CBD's pain research portfolio is considerably more developed than CBG's — with a more extensive neuropathic pain model literature, more mechanistic characterization, and the human trial data covered in the CBD and Pain Research article in this pillar. The mechanisms overlap in important ways: both interact with TRPV1, both have anti-inflammatory activity relevant to pain sensitization, and both operate without the psychoactivity of THC.

The key pharmacological difference in pain contexts is CB1. CBD has minimal CB1 agonist activity — its analgesic mechanisms are primarily TRPV1-driven, serotonergic (5-HT1A), and endocannabinoid-mediated (FAAH inhibition increasing anandamide). CBG adds partial CB1 agonism to a similar TRPV1 and anti-inflammatory profile, which gives it a distinct mechanistic character in pain models. Whether that CB1 contribution translates meaningfully at human oral doses — where bioavailability limits the fraction reaching spinal cord CB1 receptors — has not been investigated.

The Honest Evidence Summary

CBG has documented analgesic activity in standard preclinical nociception and inflammatory pain models, operating through at least three distinct mechanisms: CB1 partial agonism, TRPV1 interaction and desensitization, and anti-inflammatory CB2/PPAR-γ activity. In some nociception model comparisons, CBG produced larger analgesic effects than equivalent doses of THC — a finding that reflects its multi-mechanism profile rather than superior CB1 potency. Its neuropathic pain preclinical evidence is limited.

No human clinical trial has examined CBG for any pain condition as of 2026. The gap between preclinical nociception models and clinical pain conditions is substantial in cannabinoid research — the human pain trial evidence for CBD provides the clearest picture of what the translation from promising preclinical pain signals to demonstrated human analgesic effect actually requires. CBG's preclinical pain profile is pharmacologically coherent and worth continued investigation. The clinical evidence has not yet been generated.

References

  1. Borrelli, F., Fasolino, I., Romano, B., et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316.
  2. Cascio, M.G., Gauson, L.A., Stevenson, L.A., et al. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha-2-adrenoceptor agonist and moderately potent 5HT1A receptor agonist. British Journal of Pharmacology, 159(1), 129–141.
  3. De Petrocellis, L., Ligresti, A., Moriello, A.S., et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494.
  4. Farrimond, J.A., Whalley, B.J., & Williams, C.M. (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 223(1), 117–129.
  5. Izzo, A.A., Borrelli, F., Capasso, R., et al. (2009). Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30(10), 515–527.
  6. Pertwee, R.G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.
  7. Russo, E.B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4(1), 245–259.
Health Topics — Pain & Inflammation — Standard Research · Tier 2
Last Reviewed: August 2026

These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.